Your browser doesn't support javascript.
loading
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922.
Owens, David R; Monnier, Louis; Ceriello, Antonio; Bolli, Geremia B.
Afiliação
  • Owens DR; Diabetes Research Unit, University of Swansea Medical School, Wales, UK.
  • Monnier L; Institute of Clinical Research, University of Montpellier, Montpellier, France.
  • Ceriello A; IRCCS MultiMedica, Milan, Italy.
  • Bolli GB; Department of Medicine, University of Perugia, Perugia, Italy.
Diabetes Obes Metab ; 24 Suppl 1: 27-42, 2022 01.
Article em En | MEDLINE | ID: mdl-34708913
During 1921 to 1922, a team effort by Banting, Macleod, Collip and Best isolated and purified insulin and demonstrated its life-giving properties, giving rise to the birth of insulin therapy. In the early years (1922-1950), priorities revolved around the manufacture of insulin to meet demand, improving purity to avoid allergic reactions, establishing insulin standards and increasing its duration of action to avoid multiple daily injections. Shortly after the emergence of insulin, Joslin and Allen advocated the need to achieve and maintain good glycaemic control to realize its full potential. Although this view was opposed by some during a dark period in the history of insulin, it was subsequently endorsed some 60 years later endorsed by the Diabetes Control and Complications Trial and United Kingdom Prospective Diabetes Study. Major scientific advances by the Nobel Laureates Sanger, Hodgkin, Yalow and Gilbert and also by Steiner have revolutionized the understanding of diabetes and facilitated major advances in insulin therapy. The more recent advent of recombinant technology over the last 40 years has provided the potential for unlimited source of insulin, and the ability to generate various insulin 'analogues', in an attempt to better replicate normal insulin secretory patterns. The emerging biosimilars now provide the opportunity to improve availability at a lower cost.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / Insulina Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / Insulina Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2022 Tipo de documento: Article
...